Mizuho analyst Anthony Petrone raised the firm’s price target on Establishment Labs (ESTA) to $70 from $58 and keeps an Outperform rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Establishment Labs price target raised to $47 from $38 at Citi
- Establishment Labs Holdings: Strong Buy Rating Driven by Motiva Implants’ Growing Demand and Innovation
- Strong Buy Recommendation for Establishment Labs Holdings Driven by US Launch Momentum and Promising Pipeline
- Promising Outlook for Establishment Labs: Buy Rating Affirmed Amid Strong Market Potential and Financial Guidance
- Establishment Labs Holdings: Strong Growth Potential and Strategic Initiatives Drive Buy Rating